Trial Profile
A study to evaluate durable disease control with sunitinib and everolimus in well-differentiated in patients with neuroendocrine tumors of the pancreas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary) ; Cisplatin; Etoposide
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 02 Sep 2015 New trial record